IRWD — Ironwood Pharmaceuticals Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMid CapTurnaround

Annual income statement for Ironwood Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	390	414	411	443	351
Cost of Revenue
Gross Profit	386	414	411	—	—
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Total Operating Expenses	247	181	160	1,388	258
Operating Profit	143	232	250	-945	93.1
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	109	201	252	-948	65.2
Provision for Income Taxes
Net Income After Taxes	106	528	175	-1,032	0.88
Minority Interest
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	106	528	175	-1,002	0.88
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	106	528	180	-1,002	0.88
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.743	3.21	0.964	0.676	0.016